Opada Alzohaili, MD
Endocrinology, Diabetes & Metabolism · Dearborn, MINPI 1912942582
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.3%. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 549 payments — averaging $60.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$6K
- Medtronic$5K
- Pfizer$4K
- Sanofi-aventis U.S. LLC$4K
- Novo Nordisk$2K
- Abbott$2K
- plus $10K from 54 others
Across 46 payments — averaging $2579.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$68K
- Rhythm Pharmaceuticals, Inc.$40K
- Vertex$11K
What the payments were for
- Consulting fees$10,96233%
- Speaking & faculty fees$6,79020%
- Travel & lodging$1,0863%
- Food & beverage$14,41443%
- Education$1711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$6,056
- NGENLA$3,600
- TZIELD$3,435
- FreeStyle Libre Pro$1,675
- MINIMED 780G$1,644
- Minimed 670G System$1,043
- CeQur Simplicity$475
- Kerendia$350
- Wegovy$242
- Monoferric$231
- INJECTAFER$230
- AFREZZA$222
- Eversense$176
- Korlym$150
- FreeStyle Libre$136
- BD NANO$135
- FREESTYLE LIBRE 3$133
- LIBTAYO$130
- Sogroya$127
- TLANDO$125
How this compares
$33,423 in reported general payments places this provider in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,041 | $1,179,555 |
| JardianceEmpagliflozin | 1,446 | $1,110,516 |
| GenotropinSomatropin | 362 | $720,330 |
| TrulicityDulaglutide | 544 | $624,811 |
| FarxigaDapagliflozin Propanediol | 631 | $446,773 |
| MounjaroTirzepatide | 301 | $359,996 |
| JanuviaSitagliptin Phosphate | 371 | $258,942 |
| Norditropin FlexproSomatropin | 84 | $172,919 |
| Nutropin Aq NuspinSomatropin | 79 | $141,213 |
| JanumetSitagliptin Phos/Metformin Hcl | 165 | $130,443 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 70 | $122,654 |
| Humulin R U-500Insulin Regular, Human | 57 | $114,441 |
| OmnitropeSomatropin | 72 | $112,307 |
| TradjentaLinagliptin | 130 | $72,318 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 79 | $64,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr, Synjardy | $55 | $1,261,0471,688 claims |
| Novo NordiskOzempic, Rybelsus, Sogroya | $2,296 | $1,260,1001,109 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $853 | $984,806845 claims |
| PfizerGenotropin | $3,714 | $720,330362 claims |
| AstraZenecaFarxiga | $399 | $446,773631 claims |
| MerckJanuvia, Janumet, Janumet Xr | $182 | $439,574599 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,614 | $64,71779 claims |
| Radius Health, Inc.Tymlos | $199 | $50,20319 claims |
| Johnson & JohnsonInvokana | $141 | $37,02937 claims |
| AmgenProlia | $1,479 | $28,32917 claims |
| BayerKerendia | $428 | $27,01135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Dearborn
- Mohammad SalehDearborn$19K
- Ali AchiraDearborn$9K
- Sara TothDearborn$8K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.